Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901886003> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2901886003 endingPage "38" @default.
- W2901886003 startingPage "31" @default.
- W2901886003 abstract "Therapy with immune checkpoints inhibitors (anti-PD-1 therapy) has become the standard of care for metastatic renal cell carcinoma (mRCC) patients with resistance to tyrosine kinase inhibitors (TKI). Identification of reliable predictive markers for anti-PD-1 therapy would help to select patients who are most likely to respond to checkpoints inhibitors. This article represents the results of treatment of 23 mRCC patients who received nivolumab as part of the expanded access program in Russia. All patients demonstrated resistance to previous lines of TKI therapy. Overall response rate for nivolumab was 21.7 % with median progression-free survival of 4 months (95%CI=1.37–10.04). The median overall survival was not reached with the median follow-up of 10 months (3–14 months). The grade 3–4 toxicity was observed in 3 (13 %) pts. Favorable MSKCC prognosis before treatment, the initial level of sPD-1 exceeding the estimated threshold value and the development of any grade hypothyroidism after treatment initiation were associated with greater progression free survival. The number of preceding lines of TKI therapy, the level of PD-L1 and FOXP3 expression on tumor-infiltrating leukocytes (TILs) did not significantly affect progression-free survival in this group of mRCC patients. The ef ficacy and toxicity profile of nivolumab corresponded to the results of phase 2–3 trials." @default.
- W2901886003 created "2018-11-29" @default.
- W2901886003 creator A5015990306 @default.
- W2901886003 creator A5020683908 @default.
- W2901886003 creator A5055109644 @default.
- W2901886003 creator A5069295806 @default.
- W2901886003 creator A5076823180 @default.
- W2901886003 date "2018-11-13" @default.
- W2901886003 modified "2023-10-05" @default.
- W2901886003 title "OUTCOME OF METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED BY ANTI-PD-1 THERAPY IN EXPANDED ACCESS PROGRAM: CLINICAL EFFICACY AND POTENTIAL BIOMARKERS FOR NIVOLUMAB THERAPY" @default.
- W2901886003 cites W1901452696 @default.
- W2901886003 cites W1999075493 @default.
- W2901886003 cites W2077968480 @default.
- W2901886003 cites W2108389924 @default.
- W2901886003 cites W2148706732 @default.
- W2901886003 cites W2165625761 @default.
- W2901886003 cites W2222086386 @default.
- W2901886003 cites W2345307430 @default.
- W2901886003 cites W2378803961 @default.
- W2901886003 cites W2411664162 @default.
- W2901886003 cites W2549797787 @default.
- W2901886003 doi "https://doi.org/10.18027/2224-5057-2018-8-3-31-38" @default.
- W2901886003 hasPublicationYear "2018" @default.
- W2901886003 type Work @default.
- W2901886003 sameAs 2901886003 @default.
- W2901886003 citedByCount "2" @default.
- W2901886003 countsByYear W29018860032021 @default.
- W2901886003 crossrefType "journal-article" @default.
- W2901886003 hasAuthorship W2901886003A5015990306 @default.
- W2901886003 hasAuthorship W2901886003A5020683908 @default.
- W2901886003 hasAuthorship W2901886003A5055109644 @default.
- W2901886003 hasAuthorship W2901886003A5069295806 @default.
- W2901886003 hasAuthorship W2901886003A5076823180 @default.
- W2901886003 hasBestOaLocation W29018860031 @default.
- W2901886003 hasConcept C121608353 @default.
- W2901886003 hasConcept C126322002 @default.
- W2901886003 hasConcept C143998085 @default.
- W2901886003 hasConcept C185926286 @default.
- W2901886003 hasConcept C2777472916 @default.
- W2901886003 hasConcept C2777701055 @default.
- W2901886003 hasConcept C2778820342 @default.
- W2901886003 hasConcept C2780030458 @default.
- W2901886003 hasConcept C2780739268 @default.
- W2901886003 hasConcept C2781230642 @default.
- W2901886003 hasConcept C29730261 @default.
- W2901886003 hasConcept C3019894029 @default.
- W2901886003 hasConcept C530470458 @default.
- W2901886003 hasConcept C535046627 @default.
- W2901886003 hasConcept C71924100 @default.
- W2901886003 hasConceptScore W2901886003C121608353 @default.
- W2901886003 hasConceptScore W2901886003C126322002 @default.
- W2901886003 hasConceptScore W2901886003C143998085 @default.
- W2901886003 hasConceptScore W2901886003C185926286 @default.
- W2901886003 hasConceptScore W2901886003C2777472916 @default.
- W2901886003 hasConceptScore W2901886003C2777701055 @default.
- W2901886003 hasConceptScore W2901886003C2778820342 @default.
- W2901886003 hasConceptScore W2901886003C2780030458 @default.
- W2901886003 hasConceptScore W2901886003C2780739268 @default.
- W2901886003 hasConceptScore W2901886003C2781230642 @default.
- W2901886003 hasConceptScore W2901886003C29730261 @default.
- W2901886003 hasConceptScore W2901886003C3019894029 @default.
- W2901886003 hasConceptScore W2901886003C530470458 @default.
- W2901886003 hasConceptScore W2901886003C535046627 @default.
- W2901886003 hasConceptScore W2901886003C71924100 @default.
- W2901886003 hasIssue "3" @default.
- W2901886003 hasLocation W29018860031 @default.
- W2901886003 hasOpenAccess W2901886003 @default.
- W2901886003 hasPrimaryLocation W29018860031 @default.
- W2901886003 hasRelatedWork W1755290823 @default.
- W2901886003 hasRelatedWork W2172244781 @default.
- W2901886003 hasRelatedWork W2415433510 @default.
- W2901886003 hasRelatedWork W2788498597 @default.
- W2901886003 hasRelatedWork W2901886003 @default.
- W2901886003 hasRelatedWork W3035071241 @default.
- W2901886003 hasRelatedWork W3048594912 @default.
- W2901886003 hasRelatedWork W3159453953 @default.
- W2901886003 hasRelatedWork W4281778520 @default.
- W2901886003 hasRelatedWork W4362587156 @default.
- W2901886003 hasVolume "8" @default.
- W2901886003 isParatext "false" @default.
- W2901886003 isRetracted "false" @default.
- W2901886003 magId "2901886003" @default.
- W2901886003 workType "article" @default.